OBJECTIVE -To evaluate efficacy and safety of switching from twice-daily exenatide to once-daily liraglutide or of 40 weeks of continuous liraglutide therapy.
G
lucagon-like peptide (GLP)-1 receptor agonists improve glycemic control and reduce weight with minimal risk of hypoglycemia (1, 2) . The first randomized head-to-head comparison of two GLP-1 receptor agonists added to oral antidiabetes agents (Liraglutide Effect and Action in Diabetes [LEAD] -6) showed that 1.8 mg once-daily liraglutide provided greater improvements in A1C and fasting plasma glucose (FPG) with lower hypoglycemia and less persistent nausea than 10 g twice-daily exenatide after 26 weeks; similar decreases in weight (ϳ3 kg) and systolic blood pressure (SBP) (2.0 -2.5 mmHg) occurred with both drugs (3) . The objectives of this 14-week extension were to assess the safety and efficacy of switching from exenatide to liraglutide, or continuing liraglutide for up to 40 weeks.
RESEARCH DESIGN AND METHODS
-The LEAD-6 design has been reported (3). Adults with type 2 diabetes inadequately controlled (A1C 7-11%) with maximally tolerated stable doses of metformin, sulfonylurea, or both for Ն3 months were randomized (1:1) to 1.8 mg liraglutide once daily or 10 g exenatide twice daily. After 26 weeks, patients continued into a nonrandomized 14-week extension: all exenatide patients were switched to 0.6 mg liraglutide once daily for 1 week, then escalated to 1.2 mg for another week, and then given a final maintenance dose of 1.8 mg. Patients originally randomized to 1.8 mg liraglutide continued. Background oral antidiabetes drugs remained unchanged, although sulfonylurea doses could be decreased by 50% if unacceptable hypoglycemia occurred.
Visits occurred at weeks Ϫ2 (screening), 0 (randomization), 4, 8, 12, 20, 26, 34 , and 40 for both groups. Efficacy and safety assessments during the extension phase (weeks 26 -40) were identical to those previously described (3) . Extension intention-to-treat (ITT) (all randomized patients exposed to trial product who entered the extension) and extension safety (all patients exposed to trial product who entered the extension) populations were used for efficacy and safety analyses, respectively. Changes from baseline (last available observation up to 26 weeks) to week 40 within each treatment group were analyzed by paired t tests. Treatment groups were not compared. Post-baseline missing values were imputed using last observation carried forward. Unless noted, mean (ϮSE) values are presented. Significance was P Ͻ 0.05. was longer for those withdrawing (12.2 years) than completers (7.9 years).
RESULTS

Efficacy
Mean A1C further decreased from 7.2% at week 26 to 6.9% at week 40 (Ϫ0.32 Ϯ 0.043%; P Ͻ 0.0001) after switching from exenatide to liraglutide, but remained similar with continued liraglutide (7.0 to 6.9%; Ϫ0.06 Ϯ 0.041%, P ϭ 0.1222) (Fig. 1A) . Additional patients reached A1C targets after switching from exenatide to liraglutide (Fig. 1B) .
After switching from exenatide to liraglutide, further reductions in FPG ( Fig.  1C ; Ϫ0.9 Ϯ 0.16 mmol/l, P Ͻ 0.0001), body weight ( Fig. 1D ; Ϫ0.9 Ϯ 0.15 kg, P Ͻ 0.0001), and SBP ( Fig. 1E ; Ϫ3.8 Ϯ 0.84 mmHg, P Ͻ 0.0001) occurred while the homeostasis model of ␤-cell function (HOMA-B) assessment increased (14.5 Ϯ 4.4%, P ϭ 0.001), consistent with the FPG reductions. In patients continuing liraglutide, reductions in FPG ( Fig. 1C ; Ϫ0.2 Ϯ 0.11 mmol/l, P ϭ 0.0973), body weight (Fig. 1D, Ϫ0 .4 Ϯ 0.15 kg, P ϭ 0.0089), and SBP ( Fig. 1E Nausea and diarrhea occurred in 3.2% of patients switching from exenatide liraglutide and 1.5% in those continuing liraglutide, whereas vomiting occurred in 0.5% switching from exenatide liraglutide and 2.0% in those continuing liraglutide.
One major hypoglycemic episode occurred in a patient continuing liraglutide, while extension rates (episodes/ patient-year) of minor hypoglycemia were 1.30 (exenatide liraglutide), down from 2.60 with exenatide at week 26 (3), and 0.74 (liraglutide). Thirteen adverse events associated with withdrawal from the extension of six patients in the exenatide liraglutide group were myocardial infarction, diarrhea (three events), impaired gastric emptying, eructation, nausea, lethargy, paraesthesia, anxiety, depressed mood, depression, and dyspnea. For two of these six patients, the adverse events associated with their withdrawal from the extension (nausea and diarrhea) had been previously reported as separate events during the 26-week exenatide treatment period.
F o u r p a t i e n t s i n t h e e x e n atide liraglutide group had seven severe adverse events (cardiac failure, myocardial infarction, cataract, chest discomfort, chronic obstructive pulmonary disease [two events], dyspnea). Five patients continuing liraglutide had eight severe adverse events (cerebral infarction, cerebrovascular accident, transient ischemic attack, acute coronary syndrome, coronary artery occlusion, portal vein thrombosis, rectal cancer, and depression). Two deaths occurred (exenatide liraglutide: myocardial infarction after 198 days of treatment; liraglutide: cerebral infarction [patient completed the study but died shortly after]). Investigators assessed all events as "unlikely" to be related to trial product.
Calcitonin levels remained at the lower level of the normal range (Ͻ1 pg/ ml) and did not differ between groups. No medullary thyroid carcinoma or pancreatitis cases were reported during the extension.
CONCLUSIONS -This extension shows that patients can be simply and safely switched from twice-daily premeal exenatide to meal-independent oncedaily liraglutide using weekly dose escalation from 0.6 to 1.2 to 1.8 mg. Conversion to liraglutide from exenatide was well tolerated and further improved glycemic control. Additional reductions in body weight and SBP occurred in both groups. Over 40 weeks, liraglutide reduced A1C by 1.3%.
The magnitude of these changes and differences between liraglutide and exenatide are consistent with results reported in phase 3 LEAD (liraglutide) (3) (4) (5) (6) (7) (8) and exenatide (9 -11) trials. The greater efficacy of liraglutide may be due to sustained levels achieved over 24 h by once-daily dosing compared with biphasic levels achieved during the 2.4-h halflife of exenatide after dosing within 1 h of breakfast and dinner (12) .
Further studies are required to investigate the durability of these responses. Given the likely preference for once-daily meal-independent dosing, liraglutide appears to be a useful addition to the diabetes treatment armamentarium.
